Abstract
The risk of treatment-induced secondary cancer in patients with malignant disease is becoming more important as the treatment of primary tumors improves and more patients survive. A possible genetic or congenital predisposition, altered immunity, and the preceding or continuing exposure to certain other agents may add to the carcinogenic potential of chemotherapy and radiotherapy. It has been observed that aggressive, though successful, treatment protocols in particular enhance the risk. Some studies have reported that up to 20% of surviving patients develop a treatment-induced secondary cancer over a ten to fifteen year period following the control of the first malignancy. Effective means for the prevention of treatment-induced cancer are therefore needed. In this article, we discuss several strategies that may reduce the risk of treatment-induced cancer; namely, new multiple-drug regimens, proton beam therapy, application of tumor sensitizers, and the use of agents that inhibit malignant transformation.
Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
J.C. Arsenau, R.W. Sponzo, D.L. Levin, et. al., Nonlymphomatous malignant tumors complicating Hodgkin’s tumor: possible association with intensive therapy. N. Engl. L. Med. 212, 1119–1122 (1972).
G.B. Hutchinson, Late neoplastic changes following medical irradiation. Cancer 37. 1102–1107 (1976).
C.C. Harris, The carcinogeneity of anticancer drugs: A hazard in man. Cancer 37. 1014–1023 (1976).
A. Cliff, A.S. Levine, Second malignancies. In: “Cancer in the Young.” (Levine, A.S., Ed.). Masson Publishing USA, Inc., 1982.
F.P. Li, Second Cancer. In: “Cancer.” (V.T. DeVita, S. Hellman, S.A. Rosenberg, Eds.), 2nd ed. J.B. Lippincott Company, Philadelphia, 1985.
A.T. Meadows, G.J. D’Angio, V. Mike, A. Banfi, C. Harris, R.D.T. Jenkin, A. Schwartz, Patterns of second malignant neoplasms in children. Cancer 40. 1903–1911 (1977).
R.E. Haselow, M. Nesbit, L.P. Cehner, F.M. Khan, R. McHugh, S.H. Levitt, Second neoplasms following megavoltage radiation in a pediatric population. Cancer 42. 1185–1191 (1978).
G.B. Zulian, R.O. Mirimanoff, Ten-year nodular sclerosis Hodgkin’s disease and second malignancies. Eur. J. Clin. Oncol. 25 659–665 (1989).
J.B. Little, H. Nagasawa, A.R. Kennedy, DNA repair and malignant transformation: Effect of X-irradiation, 12–0-tetradecanoyl-phorbol-13-acetate, and protease inhibitors on transformation and sister-chromatid exchanges in mouse 10T1/2 cells. Radiat. Res. 79, 241–255 (1979).
M.A. Bookman, D.L. Longo, Concomitant illness in patients treated for Hodgkin’s disease. Cancer Treat, Rev. 11, 77–111 (1986).
M.A. Tucker, N.C. Coleman, R. Cox, A. Varghese, S.A. Rosenberg, Risk of second cancers after treatment for Hodgkin’s disease. N. Enzl, J. Med. 318. 76–81 (1988).
D.W. Blayney, D.L. Longo, R.C. Young, M.H. Greene, S.M. Hubbard, M.G. Postal, P.L. Duffey, V.T. DeVita, Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin’s disease. N. Engl. J. Med. 316, 710–714 (1987).
A. Santoro, et al., Long term results of combined chemotherapy-radiotherapy approach in Hodgkin’s disease: Superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin. Oncol. 5 27–37 (1987).
B. Hoerni, Phase II clinical trial of a novel association of epirubicin, bleomycin, vinblastine and prednisone in Hodgkin’s disease. (Abstr.) Proc. Am. Soc. Clin. Oncol. 6 743 (1987).
R. Chibber, M.J. Ord, The mutagenic and carcinogenic properties of three second generation antitumor platinum compounds: a comparison with cisplatin. Eur. J. Clin. Oncol. 21, 27–33 (1989).
L.B. Chen, et al., Mitochondria in living cells: Effects of growth factors and tumor promoters, alterations in carcinoma cells, and targets for therapy. Cancer Cells 3 433–443 (1985).
J.S. Modica-Napolitano, J.R. Aprille, Basis for the selective cytotoxicity of rhodamine 123. Cancer Res. 47. 4361–4365 (1987).
S.D. Bernal, T.J. Lampidus, R.M. Mclsaac, L.B. Chen, Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science 222. 169–172 (1983).
Anticarcinoma activity of rhodamine 123 against a murine renal adenocarcinoma. Cancer Res. 48. 2061–2063 (1988).
T. Kitagawa, Proton beam therapy. Gan To Kagaku Ryoho, 13(4 Ptl), 878–884 (1986).
M. Austin-Seymour, J.E. Munzenrider, M. Goitein, R. Gentry, E. Gragoudas, A.M. Koehler, P. McNulty, E. Osborne, D.K. Ryugo, J. Seddon, M. Urie, L. Verhey, H.D. Suit, Progress in low-LET heavy particle therapy: intracranial and paracranial tumors and uveal melanomas. Radiat. Res. 104. 5219–5226 (1985).
A.P. Brown, M.M. Urie, R. Chisin, H.D. Suit, Proton therapy for carcinoma of the nasopharynx. A study in comparative treatment planning. Int. J. Radiat. Oncol. Biol. Phys. 16 1607–1614 (1989).
Chemical modifiers of cancer treatment. Part 1. Int. J Radiat. Oncol. Biol. Phys.. 16(4), (1989).
E.P. Malaise, M. Guichard, D.W. Siemann, (Eds.), Chemical modifiers of cancer treatment. Part 2. Int. I. Radiat. Oncol. Biol. Phvs.. 16(5) (1989).
H.P. Rutz, R.O. Mirimanoff, The potential for improvements in cancer control by a tumor-specific inhibition of the repair of potentially lethal damage. (Submitted).
H.D. Suit, The scope of the problem of primary tumor control. Cancer 61 2141–2147 (1988).
H.D. Suit, R. Mirabell, Potential impact of improvements in radiation therapy on quality of life and survival. Int. J Radiat. Oncol. Biol. Phys. 16. 891–895 (1989).
H.D. Suit, S.J. Westgate, Impact of improved local tumor control on survival. Int. J. Radiat. Oncol. Biol. Phys. 12. 453–458 (1986).
D.A. Boothman, D.K. Trask, A.B. Pardee, Inhibition of potentially lethal damage repair in human tumor cells by ß-lapachone, an activator of topoisomerase I. Cancer Res. 49. 605–612 (1989).
H.P. Rutz, J.B. Little, Modification of radiosensitivity and recovery from X ray damage in vitro by retinoic acid. Int. J. Radiat. Oncol. Biol, Phvs. 16. 1285–1288 (1989).
H.P. Rutz, J.B. Little, Retinoic acid inhibits the fixation of initial transformational damage. Carcinogenesis 10 2183–2186 (1989).
U. Saffiotti, R. Montesano, A.R. Sellakumar, S.A. Borg, Experimental cancer of the lung. Inhibition by vitamin A of the induction of tracheobronchial squamous metaplasia and squamous cell tumors. Cancer 20 857–864 (1967).
W. Bollag, Prophylaxis of chemically induced benign and malignant epithelial tumors by vitamin A acid (retinoic acid). Eur. J. Cancer 8 689–693 (1972).
W. Bollag, Therapeutic effects of an aromatic retinoic acid analog on chemically induced skin papillomas and carcinomas of mice. Eur. J. Cancer 10 731–737 (1974).
W. Bollag, H.R. Hartmann, Prevention and therapy of cancer with retinoids in animals and man. Cancer Sury. 2 293–314 (1983).
C.E. Orfanos, R. Ehlert, H. Gollnick, The retinoids. A review of their clinical pharmacology and therapeutic use. Drugs 34. 459–503 (1987).
S.M. Lippman, F.L. Meyskens, Retinoids as anticarcinogens. In: “Nutrition, Growth, and Cancer,” pp. 229–244. Alan R. Liss, Inc., 1988.
R.L. Merriman, J.S. Bertram, Reversible inhibition by retinoids of 3-methylcholanthrene (MCA) induced neoplastic transformation in C3H/10T1/2 clone 8 cells. Cancer Res, 39. 1661–1666 (1979).
K. Umezawa, H. Fukamachi, T. Hirakawa, S. Takayama, T. Matsushima, T. Sugimura, Inhibition of chemical transformation of hamster embryo cells by retinoids. Toxicol. Lett. 4 87–92 (1979).
M.J. Maas, P. Nettesheim, D.K. Beeman, J.C. Barrett, Inhibition of transformation of primary rat tracheal epithelial cells by retinoic acid. Cancer Res. 44. 5688–5691 (1984).
L. Harisidiadis, R.C. Miller, E.J. Hall, C. Borek, Vitamin A analogue inhibits radiation-induced oncogenic transformation. Nature 274. 486–487, (1978).
A.R. Kennedy, Prevention of radiation transformation in vitro. In: “Vitamins, Nutrition and Cancer,” (Prasad, Ed.), pp. 166–179, Karger, Basel, 1984.
S.J. Garte, D. Currie, J. Motz, W. Troll, Retinoic acid inhibits transformation of NIH 3T3 cells by the human H-ras oncogenes. Proc. Am. Assoc. Cancer Res. 29, 140 (1988).
A.B. Roberts, N.S. Roche, M.B. Sporn, Selective inhibition of the anchorage independent growth of myc-transfected fibroblasts by retinoic acid. Nature 315. 237–239 (1985).
L.J. Mordan, J.S. Bertram, Retinoid effects on cell-cell interaction and growth characteristics of normal and carcinogen-treated C3H/10T1/2 cells. Cancer Res. 43, 567–571 (1983).
J.D. Fitzgerald, J.C. Barrett, P. Nettesheím, Changing responsiveness of rat tracheal epithelial cells at different stages of neoplastic transformation. Carcinogenesis 7 1715–1721 (1986).
J.S. Bertram, Structure-activity relationships among various retinoids and their ability to inhibit neoplastic transformation and to increase cell adhesion in the C3H/lOTl/2 Cl 8 cell line. Cancer Res. 40 3141–3146 (1980).
J.E. Martner, J.S. Bertram, Enhanced protein phosphorylation of carcinogen-initiated 10T1/2 cells accompanies their neoplastic transformation. Carcinogenesis 7. 1301–1308 (1986).
C.J. Theile, C.P. Reynolds, M.A. Israel, Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature 313. 404–406 (1985).
A.M. Jetten, Retinoids specifically enhance the number of epithelial growth factor receptors. Nature 284. 626–629 (1980).
S.M. Lippmann, J.F. Kessler, F.L. Meyskens, Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Clin. Treat. Rep,. 71. 391–405 (1987).
J.L. Mordan, Inhibition by retinoids of platelet growth factor-dependent stimulation of DNA synthesis and cell division in density-arrested C3H10T1/2 fibroblasts. Cancer Res. 49 906–909 (1989).
M. Jurin, I.F. Tannok, Influence of Vitamin A on immunological response. Immunology 29. 283–287 (1972).
G. Dennert, R. Lotan, Effects of retinoic acid on the immune system: Stimulation of T killer cell induction. Eur. J Immunol. 8, 23–29 (1978).
Abstracts, N.C.I. Retinoids and Beta-Carotene Related to the Immune System. Retinoids and Cancer. Abstracts 350–371. Oncology Overview, pp. 79–84. NCI/ICRDB, 1986.
T.T. Amantruda, III, H.P. Koeffler, Retinoids and the Immune System. In: “Retinoids and Cell Differentiation” (M.I. Sherman, Ed.), pp. 95–99. CRC Press, Boca Raton, Florida, 1986.
I.F. Tannock, H.D. Suit, N. Marshall, Vitamin A and the radiation response of experimental tumors: an immune-mediated effect. J. Natl. Cancer Inst. 448 731–741 (1972).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1991 Springer Science+Business Media New York
About this chapter
Cite this chapter
Rutz, H.P., Mirimanoff, R.O., Little, J.B. (1991). Strategies for the Prevention of Treatment-Induced Secondary Cancer. In: Nygaard, O.F., Upton, A.C. (eds) Anticarcinogenesis and Radiation Protection 2. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-3850-9_6
Download citation
DOI: https://doi.org/10.1007/978-1-4615-3850-9_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-6718-5
Online ISBN: 978-1-4615-3850-9
eBook Packages: Springer Book Archive